It was a late night for analysts yesterday, as the American Society of Clinical Oncology (ASCO) released more than 4,000 abstracts in advance of its upcoming annual meeting at 6 pm. Read More
Finalizing the design for its planned pivotal trial of cancer vaccine rindopepimut (CDX-110) in glioblastoma multiforme (GBM), slated to start in the second half of this year, Celldex Therapeutics Inc. padded its balance sheet with a $31.5 million public offering. Read More
Global in perspective, Aeras, a nonprofit product development partnership (PDP), is singular in its focus – developing the first new preventive tuberculosis (TB) vaccines in nearly a century. Read More
Endo Pharmaceuticals Holdings Inc., of Chadds Ford, Pa., and Bioniche Life Sciences Inc., of Belleville, Ontario, said preliminary Phase III results from an interim analysis showed that Urocidin, its intravesical formulation of Mycobacterial cell wall-DNA complex, showed that the product was well tolerated. The overall one-year disease-free survival rate was 25 percent, breaking down to 35 percent for patients with only papillary tumors and 21 percent for patients with carcinoma in situ with or without papillary tumors. The study enrolled 129 patients. Read More
Seaside Therapeutics Inc., of Cambridge, Mass., announced the online publication of a review paper in ACS Chemical Neuroscience detailing the evolving scientific and drug development landscape for fragile X syndrome. Read More
